In Entamoeba histolytica infection with invasive disease, what is the recommended therapeutic approach after confirmation?

• A. Luminal agent only
• B. Systemic therapy only
• C. Both luminal and systemic therapy
• D. No therapy

Answer: (C)

Invasive Entamoeba histolytica infection requires addressing both tissue invasion and luminal carriage. A drug that reaches and acts in tissues is needed to eradicate trophozoites causing organ involvement, while a drug that stays in the gut lumen is necessary to eliminate cysts and prevent relapse or ongoing transmission from carriers.

Therefore, after confirmation of invasive disease, the recommended approach is to use systemic therapy to treat tissue invasion, followed by a luminal agent to clear residual luminal cysts. This dual approach minimizes relapse and spread. For example, a nitroimidazole such as metronidazole or tinidazole is given to address tissue trophozoites, then a luminal agent like paromomycin or diloxanide furoate is added to eradicate cysts in the gut.

Single luminal therapy would miss tissue involvement, and systemic therapy alone could leave luminal carriage intact. No therapy would obviously be inappropriate given the invasive nature of the disease.